Comparative evaluation of efficacy, safety and possibilities of second-line chemotherapy of metastatic gastric cancer
Abstract
According to published randomized studies of second-line therapy in patients diagnosed with gastric cancer, an increase in the median survival with chemotherapeutic agents (docetaxel or irinotecan) is approximately 1.5 months compared with symptomatic therapy. There are data from comparative studies evaluating the effectiveness of other targeted drugs: the use of everolimus as second-line drugs did not reveal a significant increase in OS; studies of anti-EGFR therapy (the addition of panitumumab or cetuximab to chemotherapy) as first-line therapy also did not show a significant increase in OS or PFS, respectively. The increase in OS in patients treated with a combination of ramucirumab and paclitaxel, in comparison with the placebo group and paclitaxel, can be considered clinically significant for this patient population and will allow treating this therapeutic regimen as a new standard of second-line treatment in patients with this nosology.
About the Authors
R. V. Orlova
City Clinical Oncology Centre; Saint Petersburg State University
Russian Federation
Russian Federation
N. P. Belyak
City Clinical Oncology Centre
Russian Federation
Russian Federation
S. P. Erdniev
City Clinical Oncology Centre
Russian Federation
Russian Federation
S. I. Kutukova
City Clinical Oncology Centre; First Saint Petersburg State Medical University n.a. I. P. Pavlov
Russian Federation
Russian Federation
N. V. Zhukova
City Clinical Oncology Centre
Russian Federation
Russian Federation
N. P. Popova
City Clinical Oncology Centre
Russian Federation
Russian Federation
E. Yu. Zorina
City Clinical Oncology Centre
Russian Federation
Russian Federation
I. V. Avramenko
City Clinical Oncology Centre
Russian Federation
Russian Federation
A. K. Ivanova
City Clinical Oncology Centre
Russian Federation
Russian Federation
N. Yu. Antimonik
City Clinical Oncology Centre
Russian Federation
Russian Federation
References
1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan. iarc.fr (accessed Feb 28, 2014)
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig W. Chemotherapy in advanced gastric cancer: A systematic re- view and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-09.
3. Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-18.
4. Ford HER, Marshall A, Bridgewater JA, et al, on behalf of the COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase randomised controlled trial. Lancet Oncol 2014; 15: 78-86.
5. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second- line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinscha Internistische Onkologie (AIO). Eur J Cancer2011; 47:2306-14.
6. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advan- ced or recurrent gastric cancer. Gastric Cancer 2006; 9: 14-18.
7. Kodera Y, Ito S, Mochizuki Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Can- cer (CCOG0302 study). Anticancer Res 2007; 27 (4C): 2667-71
8. Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of pac- litaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998; 9: 307-10.
9. Marcello Maugeri-Sacca, Laura Pizzuti, Domenico Sergi et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort J Exp Clin Cancer Res. 2013; 32 (1): 67.
10. Ueda S, Hironaka S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized phase III study or irinotecan (CPT-11) versus weekly paclitaxel (wPTX) fir advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 [abstract] J Clin Oncol. 2012; 30 (Suppl): 4002
11. Guimbaud R, Louvet C, Bonnetain F, Viret F, Samalin E, Gornet JM, Andrä T, Rebischung C, Bouche O, Jouve JL. Final results of the intergroup FFCDGERCOR-FNCLCC 03-07 phase III study comparing two sequences of chemotherapy in advanced gastric cancers [abstract] Ann Oncol. 2010; 21 (8): viii 250.
12. Kaya AO, Coskun U, Gumus M, Dane F, Ozkan M, Isikdogan A, Alkis N, Buyukberber S, Yumuk F, Budakoglu B, Demirci U, Berk V, Bilici A, Inal A, Arpaci E, Benekli M. Anatolian Society of Medical Oncology (ASMO) The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. J Chemother. 2012; 4:217-220.
13. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metas- tasis a er failure of prior combination chemotherapy using uo- ropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol2013; 31: 4438-44.
14. Ji SH, Lim do H, Yi SY, et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 2009; 9: 110.
15. Juttner S, Wissmann C, Jons T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-40.
16. SuzukiS, Dobashi Y, Hatakeyama Y, et al. Clinicopathological signi cance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-ß phosphorylation, and microvessel density in gastric cancer. BMC Cancer 2010; 10: 659.
17. Jung YD, Mans eld PF, Akagi M, et al. E ects of combination anti-vascular endothelial growth factor receptor and antiepider- mal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002; 38: 1133-40.
18. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in com- bination with chemotherapy as rst-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-76.
19. Van Cutsem E, de Haas S, Kang KY, et al. Bevacizumab in combination with chemotherapy as rst-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30: 2119-27.
20. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-87.
21. Fuchs CS, Tomasek J, Yong CJ, et al, for the REGARD Trial In- vestigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarci- noma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2014; 383: 31-39.
22. Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously trea- ted advanced gastric cancer: results of the randomized, doub- leblind, phase III GRANITE-1 study. J Clin Oncol 2013; 31: 3935-43.
23. Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase III trial. Lancet Oncol 2013; 14:481-89.
24. Lordick F, Kang Y-K, Chung H-C, et al, on behalf of the Arbeitsgemeinscha Internistische Onkologie (AIO) and EXPAND Investigators. Capecitabine and cisplatin with or without cetu- ximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 6: 490-99.
25. Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Ja er Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D Schwartz, Atsushi Ohtsu, для исследовательской группы RAINBOW Lancet Oncol 2014; 15: 1224-35.
Review
For citations:
Orlova R.V., Belyak N.P., Erdniev S.P., Kutukova S.I., Zhukova N.V., Popova N.P., Zorina E.Yu., Avramenko I.V., Ivanova A.K., Antimonik N.Yu. Comparative evaluation of efficacy, safety and possibilities of second-line chemotherapy of metastatic gastric cancer. Medical alphabet. 2017;3(35):17-22. (In Russ.)
Views:
283
Email this article 